Eighth International Congress on Drug Therapy in HIV Infection Glasgow, UK - 12-16 November 2006

Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.4

Daniel R Kuritzkes
Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

PURPOSE OF THE STUDY: Drug resistance testing has become an essential tool for the management of antiretroviral therapy. Increasing rates of transmission of drug-resistant virus in the United States and cost-effectives analyses support the use of drug resistance testing as an essential part of initial patient evaluation, prior to starting antiretroviral therapy. Selection of appropriately optimized background regimens for use with newer agents in salvage therapy regimens likewise depends on results of drug resistance tests. The role for therapeutic drug monitoring remains less certain. Pharmacodynamic studies provide clear evidence of exposure-response relationships for many antiretroviral drugs —particularly the protease inhibitors—but few data exist to demonstrate improved treatment response as a consequence of concentration-targeted dose adjustments with contemporary regimens. Continued study of therapeutic drug monitoring, particularly in patients with altered pharmacokinetics, such as adolescents and pregnant women, may provide the data needed to make therapeutic drug monitoring a universally accepted component of individualized patient management.

Plenary Session: Clinical Pharmacology and Resistance

2006-11-12
PL4.4

Copyright © 2006 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.

This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2006. AEGiS.